Document Detail


Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
MedLine Citation:
PMID:  23135378     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The aims of this study were to determine the serum antifactor Xa levels in patients with impaired glomerular filtration receiving low-molecular-weight heparins (LMWHs), monitor efficacy and complications during treatment, and determine the approach to dose adjustments of LMWH by using antifactor Xa levels in different levels of kidney dysfunction in a real world clinical practice. Patients with chronic kidney disease who had subcutaneous enoxaparin administration during hospitalization were included in this study. We obtained data on patient demographics, glomerular filtration rate, bleeding complications, and antifactor Xa levels. Patients were divided into four groups based on glomerular filtration rate (>60 ml/min, 30-59 ml/min, 15-29 ml/min, <15 ml/min). Target levels for antifactor Xa were accepted as 0.1-0.4 IU/ml for prophylactic use and 0.4-1.1 IU/ml for therapeutic use. There were 61 patients and 18 controls (40 women, 39 men, mean age 68 ± 12 years) available for analysis. Interpretation of antifactor Xa with regard to target levels has shown that levels were in therapeutic range in 33 patients (41.8%), subtherapeutic range in 38 patients (48.1%), and supratherapeutic range in eight patients (10.1%). Less than half of the patients at each level of kidney dysfunction had antifactor Xa levels within the therapeutic range. Three patients suffered major bleeding, two with supratherapeutic, and one with therapeutic antifactor Xa level. There were no complications of ineffective anticoagulation in patients with subtherapeutic levels. Inappropriate dosing of LMWH suggested by subtherapeutic and supratherapeutic antifactor Xa levels were very high in patients with different levels of kidney dysfunction.
Authors:
Tolga Yildirim; Timur Kocak; Yahya Buyukasik; Rahmi Yilmaz; Bulent Altun; Yunus Erdem; Mustafa Arici
Related Documents :
23213558 - Effectiveness of keishibukuryogan on chronic-stage lichenification associated with atop...
24517518 - Successful leukocytapheresis therapy in a patient with rheumatoid arthritis on maintena...
23263538 - Early sleep apnea screening on a stroke unit is feasible in patients with acute cerebra...
23043868 - Is thyroidectomy in patients with hashimoto thyroiditis more risky?
15579748 - Posterior pituitary dysfunction after traumatic brain injury.
19583148 - Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  23     ISSN:  1473-5733     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  700-4     Citation Subset:  IM    
Affiliation:
aHacettepe University Faculty of Medicine, Nephrology Department bHacettepe University Faculty of Medicine, Hematology Department, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lowering homocysteine levels may prevent cardiovascular impairments? Possible therapeutic behaviors.
Next Document:  Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual anti...